67
Participants
Start Date
July 12, 2018
Primary Completion Date
December 1, 2024
Study Completion Date
July 1, 2026
Duvelisib
This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
Venetoclax
Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
University of Miami- Sylvester Comprehensive Cancer Center, Miami
Northern Light Eastern Maine Medical Center, Brewer
Massachusetts General Hospital, Boston
Boston Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Berkshire Medical Center, Pittsfield
Secura Bio, Inc.
INDUSTRY
Dana-Farber Cancer Institute
OTHER